{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T03:57:48Z","timestamp":1784347068746,"version":"3.55.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thegreenjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Radiotherapy and Oncology"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.radonc.2023.109631","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T21:41:28Z","timestamp":1679089288000},"page":"109631","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"special_numbering":"C","title":["The role of adaptive planning in margin-reduced, MRI-guided stereotactic body radiotherapy to the prostate bed following radical prostatectomy: Post-hoc analysis of a phase II clinical trial"],"prefix":"10.1016","volume":"183","author":[{"given":"John","family":"Nikitas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting Martin","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankush","family":"Sachdeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie M.","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Low","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie K.","family":"Ballas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amar U.","family":"Kishan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.radonc.2023.109631_b0005","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0022-5347(05)63946-8","article-title":"Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer","volume":"169","author":"Han","year":"2003","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109631_b0010","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.urology.2005.06.116","article-title":"Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function (\u201ctrifecta\u201d)","volume":"66","author":"Bianco","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.radonc.2023.109631_b0015","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1016\/j.juro.2012.08.028","article-title":"The impact of anatomical radical retropubic prostatectomy on cancer control: the 30-year anniversary","volume":"188","author":"Mullins","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109631_b0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0022-5347(05)67457-5","article-title":"Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years","volume":"164","author":"Amling","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.radonc.2023.109631_b0025","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(19)31131-6","article-title":"Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial","volume":"394","author":"Widmark","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.radonc.2023.109631_b0030","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S1470-2045(19)30569-8","article-title":"Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial","volume":"20","author":"Brand","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.radonc.2023.109631_b0035","doi-asserted-by":"crossref","first-page":"e188006","DOI":"10.1001\/jamanetworkopen.2018.8006","article-title":"Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer","volume":"2","author":"Kishan","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.radonc.2023.109631_b0040","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.ijrobp.2019.03.051","article-title":"Stereotactic body radiation therapy for localized prostate cancer: a systematic review and meta-analysis of over 6,000 patients treated on prospective studies","volume":"104","author":"Jackson","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109631_b0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/cancers13040759","article-title":"Stereotactic body radiotherapy for high-risk prostate cancer: a systematic review","volume":"13","author":"Foerster","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2023.109631_b0050","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ijrobp.2018.05.040","article-title":"Multicenter trial of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer: survival and toxicity endpoints","volume":"102","author":"Meier","year":"2018","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109631_b0055","unstructured":"National Comprehensive Cancer Network. Prostate Cancer (Version 4.2022). Accessed July 20, 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/prostate.pdf."},{"key":"10.1016\/j.radonc.2023.109631_b0060","doi-asserted-by":"crossref","unstructured":"Ma TM, Ballas LK, Wilhalme H, et al. Quality-of-Life Outcomes and Toxicity Profile Among Patients with Localized Prostate Cancer After Radical Prostatectomy Treated With Stereotactic Body Radiation: The SCIMITAR Multi-Center Phase 2 Trial. Int J Radiat Oncol Biol Phys. Published online August 2022.","DOI":"10.1016\/j.ijrobp.2022.08.041"},{"key":"10.1016\/j.radonc.2023.109631_b0065","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.ijrobp.2019.11.005","article-title":"Stereotactic body radiation therapy to the prostate bed: results of a phase 1 dose-escalation trial","volume":"106","author":"Sampath","year":"2020","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2023.109631_b0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.ijrobp.2018.12.047","article-title":"Phase 1 trial of SBRT to the prostate fossa after prostatectomy","volume":"104","author":"Ballas","year":"2019","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109631_b0075","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3390\/cancers14030696","article-title":"Stereotactic radiotherapy after radical prostatectomy in patients with prostate cancer in the adjuvant or salvage setting: a systematic review","volume":"14","author":"Schr\u00f6der","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2023.109631_b0080","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/bju.14924","article-title":"Stereotactic radiotherapy for prostate bed recurrence after prostatectomy, a multicentric series","volume":"125","author":"Francolini","year":"2020","journal-title":"BJU Int"},{"key":"10.1016\/j.radonc.2023.109631_b0085","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s00345-015-1613-5","article-title":"CyberKnife stereotactic radiotherapy for isolated recurrence in the prostatic bed","volume":"34","author":"Detti","year":"2016","journal-title":"World J Urol"},{"key":"10.1016\/j.radonc.2023.109631_b0090","doi-asserted-by":"crossref","unstructured":"Kishan AU, Ma TM, Lamb JM, et al. Magnetic Resonance Imaging-Guided vs Computed Tomography-Guided Stereotactic Body Radiotherapy for Prostate Cancer: The MIRAGE Randomized Clinical Trial. JAMA Oncol. 2023;e226558.","DOI":"10.1001\/jamaoncol.2022.6558"},{"key":"10.1016\/j.radonc.2023.109631_b0095","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.radonc.2017.11.032","article-title":"Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen","volume":"126","author":"Henke","year":"2018","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109631_b0100","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ijrobp.2021.08.033","article-title":"Phase I trial of stereotactic MRI-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic ovarian cancer","volume":"112","author":"Henke","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109631_b0105","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3857\/roj.2020.00976","article-title":"Stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of liver metastases in oligometastatic patients: initial clinical experience","volume":"39","author":"Ugurluer","year":"2021","journal-title":"Radiat Oncol J"},{"key":"10.1016\/j.radonc.2023.109631_b0110","doi-asserted-by":"crossref","first-page":"2802","DOI":"10.3390\/cancers13112802","article-title":"Interfractional geometric variations and dosimetric benefits of stereotactic mri guided online adaptive radiotherapy (Smart) of prostate bed after radical prostatectomy: Post-hoc analysis of a phase ii trial","volume":"13","author":"Cao","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.radonc.2023.109631_b0115","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.ijrobp.2007.04.068","article-title":"Anatomic boundaries of the clinical target volume (prostate bed) after radical prostatectomy","volume":"69","author":"Wiltshire","year":"2007","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109631_b0120","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ijrobp.2009.02.006","article-title":"Development of RTOG consensus guidelines for the definition of the clinical target volume for postoperative conformal radiation therapy for prostate cancer","volume":"76","author":"Michalski","year":"2010","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.radonc.2023.109631_b0125","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.radonc.2020.04.007","article-title":"Prostate bed and organ-at-risk deformation: prospective volumetric and dosimetric data from a phase II trial of stereotactic body radiotherapy after radical prostatectomy","volume":"148","author":"Yoon","year":"2020","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.radonc.2023.109631_b0130","article-title":"Magnetic resonance-guided prostate stereotactic body radiation therapy with daily online plan adaptation: results of a prospective phase 1 trial and supplemental cohort","volume":"7","author":"Leeman","year":"2022","journal-title":"Adv Radiat Oncol"},{"key":"10.1016\/j.radonc.2023.109631_b0135","doi-asserted-by":"crossref","unstructured":"Nicosia L, Sicignano G, Rigo M, et al. Daily dosimetric variation between image-guided volumetric modulated arc radiotherapy and MR-guided daily adaptive radiotherapy for prostate cancer stereotactic body radiotherapy. Published online 2020","DOI":"10.1080\/0284186X.2020.1821090"},{"key":"10.1016\/j.radonc.2023.109631_b0140","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ijrobp.2011.12.035","article-title":"Inter- and intrafraction uncertainty in prostate bed image-guided radiotherapy","volume":"84","author":"Huang","year":"2012","journal-title":"Int J Radiat Oncol*Biol*Phys"},{"key":"10.1016\/j.radonc.2023.109631_b0145","doi-asserted-by":"crossref","DOI":"10.1186\/s13014-020-01743-9","article-title":"Intra-fraction displacement of the prostate bed during post-prostatectomy radiotherapy","volume":"16","author":"Bell","year":"2021","journal-title":"Radiat Oncol"}],"container-title":["Radiotherapy and Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402300169X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016781402300169X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T05:27:51Z","timestamp":1759123671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016781402300169X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":29,"alternative-id":["S016781402300169X"],"URL":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109631","relation":{},"ISSN":["0167-8140"],"issn-type":[{"value":"0167-8140","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of adaptive planning in margin-reduced, MRI-guided stereotactic body radiotherapy to the prostate bed following radical prostatectomy: Post-hoc analysis of a phase II clinical trial","name":"articletitle","label":"Article Title"},{"value":"Radiotherapy and Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.radonc.2023.109631","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109631"}}